ArticleBiochemistry and biophysics reports2026
Pro-inflammatory and autophagic pathways in lung cancer: dysregulation of key genes ADINR, C/EBPα, CHAST, ATG5, IL-1B, and DICER1-AS1.
Article in Biochemistry and biophysics reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Lung cancer is the second most prevalent malignancy in both sexes and remains the leading cause of cancer-related mortality. This study aimed to evaluate the expression profile of selected Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) signaling-related genes and long non-coding RNAs (lncRNAs), particularly those involved in pro-inflammatory and autophagic pathways, in lung cancer tissues. Methods: The expression levels of three NF-κB-associated-mRNA coding genes (CCAAT/enhancer-binding protein alpha (C/EBPα), Autophagy Protein 5 (ATG5) and Interleukin-1b (IL-1B)) and six lncRNAs (Antisense Noncoding RNA in the INK4 Locus (ANRIL), Adipogenic Differentiation-Induced Noncoding RNA (ADINR), Cardiac Hypertrophy-Associated Transcript (CHAST), DICER1 Antisense RNA 1 (DICER1-AS1), Hepatocellular Carcinoma Up-regulated Long Non-coding RNA (HULC) and NF-κB Interacting LncRNA (NKILA)) from this pathway were assessed in 42 pairs of lung cancer samples and adjacent non-tumoral tissues. Receiver operating characteristic (ROC) curve analysis was performed to evaluate the diagnostic performance of these transcripts in distinguishing tumoral from non-tumoral samples. Results: ADINR, C/EBPα, CHAST, ATG5, IL-1B, and DICER1-AS1 were significantly up-regulated in tumor samples compared with adjacent non-tumoral tissues. Among the studied genes, C/EBPα showed the highest level of up-regulation in tumor tissues, with an expression ratio of 412 (95% confidence interval (CI): 159-1075, P < 0.0001). ROC curve analysis showed that the diagnostic accuracy of the evaluated transcripts ranged from 94.12% for C/EBPα to 72.26% for ADINR. The highest positive predictive value and negative predictive value were observed for C/EBPα, at 93.02% and 95.12%, respectively. The Area Under Curve (AUC) values were 0.95 for C/EBPα, 0.84 for IL-1B, 0.79 for CHAST, 0.77 for DICER1-AS1, and 0.74 for ADINR. Conclusion: The present study indicates up-regulation of NF-κB-related pro-inflammatory and autophagy-associated transcripts in lung cancer tissues. Our findings suggest that these transcripts, particularly C/EBPα, show differential expression patterns that warrant further investigation as candidate tissue biomarkers. However, the translational impact of this study is limited by lack of functional studies. Independent validation and comparison with existing clinical diagnostics are required before any clinical application can be considered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.